Search research articles
Contact Us
Filters
Showing results (1-10 of 50) with videos related to
Page
of 5
Sort By:
Journal of Dental Research
|
October 13, 2001
The induction of micronuclei in vitro by unpolymerized resin monomers
H Schweikl, G Schmalz, T Spruss
Cancer Chemotherapy and Pharmacology
|
January 1, 1996
Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice
I Muckenschnabel, G Bernhardt, T Spruss, et al.
Archiv Der Pharmazie
|
February 24, 2001
Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloro-platinum(II) act as an immune response modifier? Part III: Progressively growing MXT-M-3,2 breast cancer stimulates the proliferation of phagocytes in B6D2F1 mice
R Schlemmer, T Spruss, G Bernhardt, et al.
Archiv Der Pharmazie
|
February 24, 2001
Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part II. Studies on the influence of [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) on the specific immune defense in MXT-M-3,2 breast cancer bearing mice
R Schlemmer, T Spruss, G Bernhardt, et al.
Journal of Cancer Research and Clinical Oncology
|
January 1, 1993
Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models
T Spruss, G Bernhardt, H Schönenberger, et al.
Archiv Der Pharmazie
|
January 5, 2002
Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound
R Schlemmer, T Spruss, G Bernhardt, et al.
Cancer Letters
|
December 5, 1998
Pharmacokinetics and tissue distribution of bovine testicular hyaluronidase and vinblastine in mice: an attempt to optimize the mode of adjuvant hyaluronidase administration in cancer chemotherapy
I Muckenschnabel, G Bernhardt, T Spruss, et al.
Archiv Der Pharmazie
|
April 28, 2000
Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process
R Schlemmer, T Spruss, G Bernhardt, et al.
Archiv Der Pharmazie
|
April 7, 1999
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action
R Schlemmer, T Spruss, G Bernhardt, et al.
Journal of Cancer Research and Clinical Oncology
|
January 1, 1995
Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma
T Spruss, G Bernhardt, H Schönenberger, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 50) with videos related to
Sort By:
Page
of 5
Journal of Dental Research
|
October 13, 2001
The induction of micronuclei in vitro by unpolymerized resin monomers
H Schweikl, G Schmalz, T Spruss
Cancer Chemotherapy and Pharmacology
|
January 1, 1996
Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice
I Muckenschnabel, G Bernhardt, T Spruss, et al.
Archiv Der Pharmazie
|
February 24, 2001
Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloro-platinum(II) act as an immune response modifier? Part III: Progressively growing MXT-M-3,2 breast cancer stimulates the proliferation of phagocytes in B6D2F1 mice
R Schlemmer, T Spruss, G Bernhardt, et al.
Archiv Der Pharmazie
|
February 24, 2001
Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part II. Studies on the influence of [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) on the specific immune defense in MXT-M-3,2 breast cancer bearing mice
R Schlemmer, T Spruss, G Bernhardt, et al.
Journal of Cancer Research and Clinical Oncology
|
January 1, 1993
Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models
T Spruss, G Bernhardt, H Schönenberger, et al.
Archiv Der Pharmazie
|
January 5, 2002
Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound
R Schlemmer, T Spruss, G Bernhardt, et al.
Cancer Letters
|
December 5, 1998
Pharmacokinetics and tissue distribution of bovine testicular hyaluronidase and vinblastine in mice: an attempt to optimize the mode of adjuvant hyaluronidase administration in cancer chemotherapy
I Muckenschnabel, G Bernhardt, T Spruss, et al.
Archiv Der Pharmazie
|
April 28, 2000
Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process
R Schlemmer, T Spruss, G Bernhardt, et al.
Archiv Der Pharmazie
|
April 7, 1999
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action
R Schlemmer, T Spruss, G Bernhardt, et al.
Journal of Cancer Research and Clinical Oncology
|
January 1, 1995
Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma
T Spruss, G Bernhardt, H Schönenberger, et al.
Page
of 5